As of December 31, 2023, Bioera S.p.A. has 20.57M shares outstanding.
| Shares Outstanding | 20.57M |
These figures are as of December 31, 2023. The price-to-sales ratio is 0.74, and the price-to-book ratio stands at -0.08.
| PS Ratio | 0.74 |
| PB Ratio | -0.08 |
| P/TBV Ratio | -0.05 |
| P/FCF Ratio | -1.25 |
| P/OCF Ratio | -0.92 |
These figures are as of December 31, 2023. The EV/Sales ratio of 2.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.
| EV / Sales | 2.75 |
As of December 31, 2023, Bioera S.p.A. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -46.64, indicating conservative leverage, while an interest coverage ratio of -15.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.08 |
| Debt / Equity | -46.64 |
| Debt / EBITDA | -4.68 |
| Interest Coverage | -15.18 |
These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -65.65, reflecting losses generated across the asset base. Inventory turnover of 1.44 indicates how many times Bioera S.p.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -65.65 |
| Inventory Turnover | 1.44 |
As of the close on March 10, 2025, Bioera S.p.A.'s stock has gained approximately 23.12% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.06.
| 52-Week Price Change | 23.12% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
Over the twelve months ended December 31, 2023, Bioera S.p.A. posted a gross margin of 55.23, reflecting its pricing power and cost economics. The operating margin of -150.54 and net profit margin of -209.92 provide insight into operational efficiency.
| Gross Margin | 55.23 |
| Operating Margin | -150.54 |
| Pretax Margin | -240.95 |
| Profit Margin | -209.92 |
| EBITDA Margin | -150.54 |
These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -80.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -155.29, meaning Bioera S.p.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -155.29 |
| FCF Yield | -80.23 |
Bioera S.p.A.'s most recent stock split took place on February 20, 2023 with a 41:56 split ratio.
| Last Split Date | 2/20/2023 |
| Split Ratio | 41:56 |
As of December 31, 2023, Bioera S.p.A. has an Altman Z-Score of -14.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -14.07 |
Already premium?